Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Introduction: Cancer cells secrete bioactive peptides that act in an autocrine or paracrine fashion affecting tumor growth and metastasis. Corticotropin-releasing factor (CRF), a hypothalamic neuropeptide that controls the response to stress, has been detected in breast cancer tissues and cell lines. CRF can affect breast cancer cells in an autocrine or paracrine manner via its production from innervating sympathetic neurons or immune cells. Methods: In the present study we report our findings regarding the impact of CRF on breast cancer cell motility and invasiveness. For this purpose we used the MCF7 breast cancer cell line and evaluated the effect of CRF on motility and invasiveness using the wound-healing and boyden-chamber assays. In addition, we measured the effect of CRF on molecules that mediate motility by western blot, immunofluorescence, ELISA and RT-PCR. Results: Our findings show that: 1. CRF transiently inhibited the apoptosis of MCF7 cells. 2. CRF enhanced MCF7 cell motility in a wound healing assay and their invasiveness through extracellular matrix. 3. CRF increased actin polymerization, phosphorylation of Focal Adhesion Kinase (FAK), providing a potential mechanism for the observed induction of MCF7 motility. 4. CRF induced the expression of Cox-1 but not Cox-2 in MCF7 cells as well as the production of prostaglandins, factors known to promote invasiveness and metastasis. Conclusion: Overall, our data suggest that CRF stimulates cell motility and invasiveness of MCF7 cells most probably via induction of FAK phosphorylation and actin filament reorganization and production of prostaglandins via Cox1. Based on these findings we postulate that the stress neuropeptide CRF present in the vicinity of tumors (either produced locally by the tumor cells themselves or by nearby normal cells or secreted from the innervations of surrounding tissues) may play an important role on breast tumor growth and metastatic capacity, providing a potential link between stress and tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CRF is widely present in the central nervous system, that has been detected in breast cancer tissues and cell lines, and affects breast cancer cell proliferation and invasion in an autocrine or paracrine manner (10).”
From Chronic Stress Promotes Cancer Development (2020) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Kargiotis, O., Chetty, C., Gondi, C. S., Tsung, A. J., Dinh, D. H., Gujrati, M., Lakka, S. S., Kyritsis, A. P., & Rao, J. S. (2008) · Oncogene · doi:10.1038/onc.2008.122 · Cited by 133 · cited 1×
“Evasion of apoptosis is a hallmark of cancer cells and is frequently associated with proliferation and invasiveness [35-38].”
RetractedWang, Z. P., Song, W., Aboukameel, A., Mohammad, M., Wang, G., Banerjee, S., Kong, D., Wang, S., Sarkar, F. H., & Mohammad, R. M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23610 · Cited by 60 · cited 1×
“2. CRF affects apoptosis of MCF7 cells in a time dependent-manner Evasion of apoptosis is a hallmark of cancer cells and is frequently associated with proliferation and invasiveness [ 35-38 ].”
RetractedCRF and CRF receptors: role in stress responsivity and other behaviors
Bale, T. L., & Vale, W. W. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121410 · Cited by 1,270 · cited 2×
“It should be noted here that CRF is constantly present in the microenvironment of tumors produced by nearby cells including endothelial cells [24] and immune cells [14] and by the local neuronal innervations [25].”
The actin cytoskeleton in cancer cell motility
Olson, M. F., & Sahai, E. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9174-2 · Cited by 572 · cited 1×
“Increased actin polymerization is associated with dynamic changes in cytoskeletal structures that allow cells to migrate and metastasize [49].”
The CRF peptide family and their receptors: yet more partners discovered
Dautzenberg, F. M., & Hauger, R. L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)01946-6 · Cited by 532 · cited 1×
“The neuropeptide CRF and its family members Urocortin (UCN)1, UCN2 and UCN3 act via two receptors, CRF1 and CRF2, subtypes of which are differentially expressed in the central nervous system (CNS) and a multitude of peripheral tissues [9,10].”
Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase.
Chen, H. C., & Guan, J. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.10148 · Cited by 513 · cited 1×
“FAK activation by phosphorylation is the first element, which may transmit extracellular signals to downstream signaling proteins, leading to actin reorganization [40, 42- 44 ] and is implicated in cell migration [33,41].”
Signalling networks regulating cyclooxygenase-2
Tsatsanis, C., Androulidaki, A., Venihaki, M., & Margioris, A. N. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.03.021 · Cited by 492 · cited 2×
“Cyclooxygenase activation and prostaglandin production has also been associated with increase in metastasis [47,55,56].”
Self-citationXiong, H., Zhang, Z.-G., Tian, X.-Q., Sun, D.-F., Liang, Q.-C., Zhang, Y.-J., Lu, R., Chen, Y.-X., & Fang, J.-Y. (2008) · Neoplasia · doi:10.1593/neo.07971 · Cited by 426 · cited 1×
“Evasion of apoptosis is a hallmark of cancer cells and is frequently associated with proliferation and invasiveness [35-38].”
Lamellipodia and filopodia in metastasis and invasion
Machesky, L. M. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.03.039 · Cited by 300 · cited 1×
“Filamentous actin is the major component of microfilaments, present in filipodia and lamellipodia, which are reported to facilitate cell migration [39].”
Cao, J., Papadopoulou, N., Kempuraj, D., Boucher, W. S., Sugimoto, K., Cetrulo, C. L., & Theoharides, T. C. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7665 · Cited by 285 · cited 1×
“The primer sets, previously reported to detect the respective CRF receptors in human brain specimen [31], were: CRF1a (272 bp): sense 5'-GGCAGCTAGTGGTTCG-”
Liu, X., & Rose, D. P. (1996) · PubMed · Cited by 273
Tremblay, L., Hauck, W., Aprikian, A. G., Bégin, L. R., Chapdelaine, A., & Chevalier, S. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19961009)68:2<169::aid-ijc4>3.0.co;2-w · Cited by 252
Urocortin Protects against Ischemic and Reperfusion Injury via a MAPK-dependent Pathway
Brar, B. K., Jonassen, A. K., Stephanou, A., Santilli, G., Railson, J., Knight, R. A., Yellon, D. M., & Latchman, D. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8508 · Cited by 236 · cited 1×
“The CRF system has been implicated in the physiology of the cardiovascular, reproductive and gastrointestinal systems [11-13].”
Kundu, N., & Fulton, A. M. (2002) · PubMed · Cited by 189
Papakonstanti, E. A., Kampa, M., Castanas, E., & Stournaras, C. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0253 · Cited by 160 · cited 1×
“In particular, FAK was found to overexpressed and to be highly activated in tumorigenic DU145 and PC-3 cells as well as in prostate cancer tissues from patients with metastasis [52,53] whereas in LNCaP cells that have a lower tumorigenic ability FAK was observed to be much lower [44,52].”
Self-citationCell responses regulated by early reorganization of actin cytoskeleton
Papakonstanti, E. A., & Stournaras, C. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.02.064 · Cited by 159 · cited 2×
“FAK activation by phosphorylation is the first element, which may transmit extracellular signals to downstream signaling proteins, leading to actin reorganization [40,4244] and is implicated in cell migration [33,41].”
Self-citationRole of prostaglandin E2 receptors in migration of murine and human breast cancer cells
Timoshenko, A. V., Xu, G., Chakrabarti, S., Lala, P. K., & Chakraborty, C. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00269-6 · Cited by 153 · cited 1×
“Cyclooxygenases (Cox), the enzymes that convert arachidonic acid into prostaglandins, have been causally linked to breast cancer cell proliferation, motility and invasiveness [45-48], thus the effect of CRF in prostaglandin production and Cox expression was investigated.”
Peripheral corticotropin-releasing hormone and urocortin in the control of the immune response
Baigent, S. (2001) · Peptides · doi:10.1016/s0196-9781(01)00395-3 · Cited by 146 · cited 3×
“Moreover, CRF peptides and their receptors are also present in the immune system and possess immunomodulatory properties [14-18].”
Adhesion-linked kinases in cancer; emphasis on Src, focal adhesion kinase and PI 3-kinase
Jones, R. J., Brunton, V., & Frame, M. C. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00153-2 · Cited by 130 · cited 1×
“FAK also seems to play a role in tumor development since it has been shown that primary human cancer cells or cell lines overexpress the protein as well as its phosphorylated form [ 51 ,52].”
Carraway, R. E., & Plona, A. M. (2006) · Peptides · doi:10.1016/j.peptides.2006.04.030 · Cited by 128 · cited 1×
“Neuropeptides and their receptors are present in the tumor microenvironment affecting cancer progression [ 1- 4 ]. Neuropeptides are known to be produced either from the tumor cells themselves or by nearby located nontumor cells, such as stroma, immune cells or by innervating autonomic neurons.”
Milde‐Langosch, K., Röder, H., Andritzky, B., Aslan, B., Hemminger, G., Brinkmann, A., Bamberger, C. M., Löning, T., & Bamberger, A. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000032982.49024.71 · Cited by 124
Boorse, G. C., & Denver, R. J. (2006) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2005.11.014 · Cited by 118 · cited 1×
“The neuropeptide CRF and its family members Urocortin (UCN)1, UCN2 and UCN3 act via two receptors, CRF1 and CRF2, subtypes of which are differentially expressed in the central nervous system (CNS) and a multitude of peripheral tissues [9,10].”
Basu, G. D., Liang, W. S., Stephan, D. A., Wegener, L. T., Conley, C. R., Pockaj, B. A., & Mukherjee, P. (2006) · Breast Cancer Research · doi:10.1186/bcr1626 · Cited by 110 · cited 1×
“Cyclooxygenases (Cox), the enzymes that convert arachidonic acid into prostaglandins, have been causally linked to breast cancer cell proliferation, motility and invasiveness [45-48], thus the effect of CRF in prostaglandin production and Cox expression was investigated.”
Connolly, E., Harmey, J. H., O’Grady, T. J., Foley, D., Roche‐Nagle, G., Kay, E., & Bouchier‐Hayes, D. J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600462 · Cited by 107
Kallergi, G., Agelaki, S., Markomanolaki, H., Georgoulias, V., & Stournaras, C. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110458 · Cited by 106 · cited 4×
“To quantify the extent of actin polymerization that occurred in the presence of CRF we analyzed the amount of monomeric G actin and compared it to the expression of total actin (monomeric G and polymeric F) providing the ratio between the two forms as previously reported [ 33 ,40,41].”
InfluentialSelf-citationSurowiak, P., Materna, V., Matkowski, R., Szczuraszek, K., Kornafel, J. A., Wojnar, A., Pudełko, M., Dietel, M., Denkert, C., Zabel, M., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1313 · Cited by 92 · cited 1×
“Cyclooxygenase activation and prostaglandin production has also been associated with increase in metastasis [47,55,56].”
Dermitzaki, E., Tsatsanis, C., Gravanis, A., & Margioris, A. N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111236200 · Cited by 90 · cited 4×
“Western blot analysis of proteins for the detection of tubulin (Chemicon, USA), Cox-1 (Chemicon, USA) and Cox2 (Santa Cruz, California, USA) was performed as previously described [28].”
InfluentialSelf-citationHiraga, T., Myoui, A., Choi, M. E., Yoshikawa, H., & Yoneda, T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2012 · Cited by 89 · cited 1×
“Cyclooxygenases (Cox), the enzymes that convert arachidonic acid into prostaglandins, have been causally linked to breast cancer cell proliferation, motility and invasiveness [45-48], thus the effect of CRF in prostaglandin production and Cox expression was investigated.”
Tsatsanis, C., Androulidaki, A., Alissafi, T., Charalampopoulos, I., Dermitzaki, E., Roger, T., Gravanis, A., & Margioris, A. N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1869 · Cited by 88
Self-citationBarnes, N. L. P., Wärnberg, F., Farnie, G., White, D. J., Jiang, W. G., Anderson, E. L., & Bundred, N. J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603593 · Cited by 85 · cited 1×
“Inhibition of Cox-2 is associated with decrease in tumor growth and invasiveness [56,57].”
Urocortin in Human Gastric Mucosa: Relationship to Inflammatory Activity
Chatzaki, Ε., Charalampopoulos, I., Leontidis, C., Mouzas, I., Tzardi, M. N., Tsatsanis, C., Margioris, A. N., & Gravanis, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020853 · Cited by 84 · cited 1×
“The CRF system has been implicated in the physiology of the cardiovascular, reproductive and gastrointestinal systems [11-13].”
Self-citationPapadopoulou, N., Charalampopoulos, I., Alevizopoulos, K., Gravanis, A., & Stournaras, C. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.07.012 · Cited by 82 · cited 1×
“In particular, FAK was found to overexpressed and to be highly activated in tumorigenic DU145 and PC-3 cells as well as in prostate cancer tissues from patients with metastasis [52,53] whereas in LNCaP cells that have a lower tumorigenic ability FAK was observed to be much lower [44,52].”
Self-citationFunasaka, Y., Sato, H., Chakraborty, A. K., Ohashi, A., Chrousos, G. P., & Ichihashi, M. (1999) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/sj.jidsp.5640192 · Cited by 71
Graziani, G. (2002) · Endocrinology · doi:10.1210/en.143.3.807 · Cited by 70 · cited 3×
“It has been previously reported that CRF has antiproliferative effects on cancer cell lines such as Ishikawa endometrial carcinoma cells and in MCF7 stimulated by estrogens [5,23].”
Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation
MINAS, V., Rolaki, A., Kalantaridou, S., Sidiropoulos, J., Mitrou, S., Petsas, G. K., Jeschke, U., Paraskevaidis, E., Fountzilas, G., Chrousos, G. P., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603918 · Cited by 67
Agnello, D., Bertini, R., Sacco, S., Meazza, C., Villa, P., & Ghezzi, P. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.275.5.e757 · Cited by 65 · cited 1×
“Moreover, CRF peptides and their receptors are also present in the immune system and possess immunomodulatory properties [14-18].”
McEvoy, A. N., Bresnihan, B., FitzGerald, O., & Murphy, E. P. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200108)44:8<1761::aid-art311>3.0.co;2-d · Cited by 65
Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation
Hao, Z., Huang, Y., Cleman, J., Jovin, I. S., Vale, W., Bale, T. L., & Giordano, F. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712366105 · Cited by 64 · cited 2×
“Given recent findings for the anti-tumor properties of CRF2 agonists [30] and the lack of CRF2 expression on breast cancer cells one may suggest that inhibition of CRF1 and activation of CRF2 may successfully inhibit tumor growth.”
Radulović, M., Hippel, C., & Spiess, J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01594.x · Cited by 63 · cited 3×
“e in Y79 neuroblastoma cells CRF inhibited caspase 3 activity [29], while PC12 cells undergo apoptosis in response to CRF due to production of FasL [28], which is not expressed in MCF7 cells.”
Corticotropin-Releasing Hormone Stimulates Angiogenesis and Epithelial Tumor Growth in the Skin
Arbiser, J. L., Karalis, K. P., Viswanathan, A. N., Koike, C., Anand‐Apte, B., Flynn, E. A., Zetter, B. R., & Majzoub, J. A. (1999) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1999.00760.x · Cited by 57 · cited 1×
“It should be noted here that CRF is constantly present in the microenvironment of tumors produced by nearby cells including endothelial cells [24] and immune cells [14] and by the local neuronal innervations [25].”
Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs.
Carlson, K. W., Nawy, S. S., Wei, E. T., Sadée, W., Filov, V. A., Rezsova, V. V., Slominski, A. T., & Quillan, J. M. (2001) · PubMed · Cited by 57
Slominski, A. T., Roloff, B., Zbytek, B., Wei, E. T., Fechner, K., Curry, J. L., & Wortsman, J. (2000) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1290/1071-2690(2000)036<0211:crharp>2.0.co;2 · Cited by 57 · cited 1×
“Moreover, CRF and CRF related peptides, sauvagine and UCN, inhibit the proliferation of human HaCaT keratinocytes via CRF1 [27].”
Graziani, G., Tentori, L., Muzi, A., Vergati, M., Tringali, G., Pozzoli, G., & Navarra, P. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.10.006 · Cited by 56
Slominski, A. T., Roloff, B., Zbytek, B., Wei, E. T., Fechner, K., Curry, J. L., & Wortsman, J. (2000) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1290/1071-2690(2000)036<0201:ahsemt>2.0.co;2 · Cited by 56
Expression of the Tpl2/Cot oncogene in human T-cell neoplasias.
Christoforidou, A., Papadaki, H. Α., Margioris, A. N., Eliopoulos, G. D., & Tsatsanis, C. (2004) · Molecular Cancer · doi:10.1186/1476-4598-3-34 · Cited by 56
Self-citationBasson, M. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2992 · Cited by 54
Koukouritaki, S. B., Gravanis, A., & Stournaras, C. (1999) · Molecular Medicine · doi:10.1007/bf03402097 · Cited by 53
Self-citationOhue, M., Tomita, N., Monden, T., Miyoshi, Y., Ohnishi, T., Izawa, H., Kawabata, Y., Sasaki, M., Sekimoto, M., Nishisho, I., et al. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19961009)68:2<203::aid-ijc11>3.0.co;2-b · Cited by 47
Kowal‐Bielecka, O., Distler, O., Neidhart, M., K�nzler, P., Rethage, J., Nawrath, M., Carossino, A. M., Pap, T., M�ller-Ladner, U., Michel, B. A., et al. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200108)44:8<1865::aid-art325>3.0.co;2-m · Cited by 44
Actin Cytoskeleton Architecture and Signaling in Osmosensing
Papakonstanti, E. A., & Stournaras, C. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)28012-7 · Cited by 37 · cited 2×
“The quantification of actin was performed by reference to a standard curve, prepared from muscle actin [34].”
Self-citationAlpha-melanocyte stimulating hormone peptide-targeted melanoma imaging
Miao, Y., & Quinn, T. P. (2007) · Frontiers in bioscience · doi:10.2741/2406 · Cited by 37
The Expression of Corticotropin‐Releasing Hormone in Melanoma
Sato, H., Nagashima, Y., Chrousos, G. P., Ichihashi, M., & Funasaka, Y. (2002) · Pigment Cell Research · doi:10.1034/j.1600-0749.2002.1o063.x · Cited by 36 · cited 3×
“Earlier studies had shown that CRF suppressed breast cancer cell proliferation while it promoted proliferation in melanoma cells [6].”
Kallergi, G., Tsapara, A., Kampa, M., Papakonstanti, E. A., Krasagakis, K., Castanas, E., & Stournaras, C. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00210-6 · Cited by 32 · cited 2×
“FAK activation by phosphorylation is the first element, which may transmit extracellular signals to downstream signaling proteins, leading to actin reorganization [40,4244] and is implicated in cell migration [33,41].”
Self-citationA novel splice variant of occludin deleted in exon 9 and its role in cell apoptosis and invasion
Gu, J.-M., Lim, S. O., Park, Y. M., & Jung, G. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06467.x · Cited by 31 · cited 1×
“Evasion of apoptosis is a hallmark of cancer cells and is frequently associated with proliferation and invasiveness [35-38].”
Corticotropin-releasing hormone (CRH) and immunotolerance of the fetus
Makrigiannakis, A., Zoumakis, E., Kalantaridou, S., Mitsiades, N., Margioris, A. N., Chrousos, G. P., & Gravanis, A. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01547-2 · Cited by 31
Self-citationSashinami, H., Kageyama, K., Suda, T., & Nakane, A. (2005) · Endocrinology · doi:10.1210/en.2005-0439 · Cited by 31 · cited 1×
“Moreover, CRF peptides and their receptors are also present in the immune system and possess immunomodulatory properties [14-18].”
Calcium-dependent growth regulation of small cell lung cancer cells by neuropeptides
Gudermann, T. W., & Roelle, S. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01302 · Cited by 31 · cited 1×
“Neuropeptides and their receptors are present in the tumor microenvironment affecting cancer progression [ 1- 4 ]. Neuropeptides are known to be produced either from the tumor cells themselves or by nearby located nontumor cells, such as stroma, immune cells or by innervating autonomic neurons.”
Schoeffter, P., Feuerbach, D., Bobimac, I., Gazi, L., & Longato, R. (1999) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1999.tb00007.x · Cited by 28 · cited 1×
“Several neuroendocrine tumor cell lines such as the PC12 pheochromocytoma, Y79 retinoblastoma, IMR-32 and SH-SY5Y neuroblastoma, AtT-20 pituitary carcinoma and NCI-H82 small cell lung cancer cell lines express CRF and the CRF1 receptor [19-22].”
Functional corticotropin-releasing factor receptors in human neuroblastoma cells
Dieterich, K. D., & DeSouza, E. B. (1996) · Brain Research · doi:10.1016/0006-8993(96)00752-4 · Cited by 27 · cited 1×
“Several neuroendocrine tumor cell lines such as the PC12 pheochromocytoma, Y79 retinoblastoma, IMR-32 and SH-SY5Y neuroblastoma, AtT-20 pituitary carcinoma and NCI-H82 small cell lung cancer cell lines express CRF and the CRF1 receptor [19-22].”
Corticotropin-releasing factor family and its receptors: Tumor therapeutic targets?
Wang, J., & Li, S. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.014 · Cited by 25 · cited 1×
“Several neuroendocrine tumor cell lines such as the PC12 pheochromocytoma, Y79 retinoblastoma, IMR-32 and SH-SY5Y neuroblastoma, AtT-20 pituitary carcinoma and NCI-H82 small cell lung cancer cell lines express CRF and the CRF1 receptor [19-22].”
Gutknecht, E., Hauger, R. L., der Linden, I. V., Vauquelin, G., & Dautzenberg, F. M. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05052.x · Cited by 20
The VIP-receptor system in neuroblastoma cells
Jm, M., Philippe, M., Chevrier, L., Héraud, C., Alleaume, C., & Chadéneau, C. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.06.014 · Cited by 20
Cited by
Chronic Stress Promotes Cancer Development
Dai, S., Mo, Y., Wang, Y., Xiang, B., Liao, Q., Zhou, M., Li, X., Li, Y., Xiong, W., Li, G., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01492 · Cited by 405
“CRF and Thyroid Hormone CRF is widely present in the central nervous system, that has been detected in breast cancer tissues and cell lines, and affects breast cancer cell proliferation and invasion in an autocrine or paracrine manner (10).”
BackgroundHaakensen, V. D., Bjøro, T., Lüders, T., Riis, M., Bukholm, I. K., Kristensen, V. N., Troester, M. A., Homen, M. M., Ursin, G., Børresen‐Dale, A., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-332 · Cited by 53
“has a carcinogenic role in different epithelial cancers [37-41].”
BackgroundHang, Z., Lei, T., Zeng, Z., Cai, S., Bi, W., & Du, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112343 · Cited by 47
Zhu, C., Sun, Z., Li, C., Guo, R., Li, L., Jin, L., Wan, R., & Li, S. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.02.002 · Cited by 38
The corticotropin releasing factor system in cancer: expression and pathophysiological implications
Kaprara, A., Pazaitou‐Panayiotou, K., Kortsaris, A., & Chatzaki, Ε. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0265-2 · Cited by 38
“Interestingly, while CRF transiently inhibited apoptosis, it also promoted cell motility and invasiveness most probably via induction of focal adhesion kinase phosphorylation, actin filament reorganization, and production of prostaglandins via Cox 1 [ 40 ].”
Background
Metadata
- Authors
- Androulidaki, A., Dermitzaki, E., Venihaki, M., Karagianni, E., Rassouli, O., Andreakou, E., Stournaras, C., Margioris, A. N., & Tsatsanis, C.
- Affiliations
- University of Crete (GR)
- Corresponding author
- Margioris, Andrew N
- Tsatsanis, Christos
- Venue
- Molecular Cancer
- Published
- 2009-06-02
- Volume
- 8
- Issue
- 1
- Pages
- 30-30
- ISSN
- 1476-4598 (ISSN-L)
- PMC
- PMC2697132
- OpenAlex
- W2138640721
- Cited by
- 58
- References
- 59
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 3 · 2015: 4 · 2014: 4 · 2013: 5 · 2012: 1
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Molecular Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- corticotropin-releasing factor, breast cancer, cell motility, tumor invasion, MCF-7 cells, apoptosis inhibition, focal adhesion kinase phosphorylation, actin polymerization, cyclooxygenase-1, prostaglandins, metastasis, tumor microenvironment
- MeSH terms
- Actins, Analysis of Variance, Breast Neoplasms, Cell Movement, Corticotropin-Releasing Hormone, Enzyme-Linked Immunosorbent Assay, Female, Fluorescent Antibody Technique, Humans, Neoplasm Invasiveness, Phosphorylation, Prostaglandins, Blotting, Western, Apoptosis, Reverse Transcriptase Polymerase Chain Reaction, Cell Line, Tumor, Focal Adhesion Kinase 1, Cyclooxygenase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.